Nonantipsychotic Therapy for Monosymptomatic Auditory Hallucinations

Biological psychiatry (Impact Factor: 10.26). 10/2010; 68(7):e33-4. DOI: 10.1016/j.biopsych.2010.04.026
Source: PubMed
12 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Scales to measure the severity of different dimensions of auditory hallucinations and delusions are few. Biochemical and psychological treatments target dimensions of symptoms and valid and reliable measures are necessary to measure these. The inter-rater reliability and validity of the Psychotic Symptom Rating Scales (PSYRATS: auditory hallucination subscale and delusions subscale), which measure several dimensions of auditory hallucinations and delusions were examined in this study. The two scales were found to have excellent inter-rater reliability. Their validity as compared with the KGV scale (Krawiecka et al. 1977) was explored. It is concluded that the PSYRATS are useful assessment instruments and can complement existing measures.
    Psychological Medicine 08/1999; 29(4):879-89. DOI:10.1017/S0033291799008661 · 5.94 Impact Factor
  • Journal of Neuropsychiatry 02/2001; 13(3):425-7. DOI:10.1176/appi.neuropsych.13.3.425 · 2.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The sudden interest in initiating treatment before the onset of psychosis (i.e., during the prodromal stage of schizophrenia) has failed to integrate the earlier work on prediction generated by more traditional high-risk studies. Genetic high-risk research has most typically focused on the long-term, prospective study of children of parents with schizophrenia. In this paper, it will be argued that high-risk research can make at least two major contributions to prevention programs. First, previous findings can guide identification of risk factors and provide clues about causality, thus highlighting which pre-morbid deficits should be treatment targets. For example, as discussed here, data from the New York High Risk Project points to impaired attention as a highly promising candidate risk factor, with a possible causal association with later-emerging social deficits. Second, the high-risk approach can provide a framework for establishing the predictive validity of prodromal clinical indicators and for understanding the nature of the schizophrenia prodrome. Preliminary findings from the Hillside Recognition and Prevention (RAP) program, integrating high-risk methodology with an early intervention strategy, indicate that the prodrome is a developmentally complex phase of schizophrenia. In particular, a cluster of early features-including cognitive, academic, and social impairments, along with odd/disorganized behaviors-appear to anticipate positive symptoms and may constitute a core risk profile. Preliminary RAP treatment findings also suggest that medications other than anti-psychotics may be effective for treating early prodromal symptoms, challenging the widely held hypothesis that anti-psychotics should always be the first line preventive treatment.
    American Journal of Medical Genetics 12/2002; 114(8):956-66. DOI:10.1002/ajmg.b.10520 · 3.23 Impact Factor